A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

Part of paid clinical trials in South Miami, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT06039826
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
40 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3437943 — DRUG
    Administered SC.
  • Ethinyl Estradiol — DRUG
    Administered orally
  • Drospirenone — DRUG
    Administered orally

Study Details

The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant.

Key Dates

Start date
Sep 12, 2023
Status verified
Jul 2024
Primary completion
Jul 11, 2024
Completion
Jul 11, 2024

Study Design

Enrollment
46 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3437943 + Combined Oral Contraceptive (COC)
    The COC ethinyl estradiol and drospirenone administered orally in combination with LY3437943 administered subcutaneously (SC).

Primary Outcome Measure

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Ethinyl Estradiol [ Time Frame: Predose on Day 1 up to 144 days postdose ]

Locations (2)

FacilityCityStateZIPSite coordinators
Qps-Mra, LlcSouth MiamiFlorida33143-
ICON Early Phase ServicesSan AntonioTexas78209-

Find similar trials in South Miami, FL

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Qps-Mra, Llc· South Miami, FLICON Early Phase Services· San Antonio, TX

Related Studies